CONFERENCE-AT-A-GLANCE

**Monday** | **Tuesday - Wednesday a.m.** | **Wednesday p.m. - Thursday**
---|---|---
Pre-Conference Short Courses | **T1A**: Targeting Epigenetic Readers and Chromatin Remodelers | **T1B**: Targeting Histone Methyltransferases and Demethylases
 | **T2A**: Targeting the Ubiquitin Proteosome System | **T2B**: Targeting the Unfolded Protein Response
S1: Symposium: Next Generation Histone Deacetylase Inhibitors | **T3A**: Targeting the Microbiome | **T3B**: Kinase Inhibitor Discovery
 | **T4A**: GPCR-Based Drug Discovery – Part 1 | **T4B**: GPCR-Based Drug Discovery – Part 2
 | **T5A**: Antibodies Against Membrane Protein Targets – Part 1 | **T5B**: Antibodies Against Membrane Protein Targets – Part 2
 | **T6A**: RNAi for Functional Genomics Screening | **T6B**: New Frontiers in Gene Editing
S2: Symposium: Strategies for Rare Diseases | **T7A**: Gene Therapy Breakthroughs | **T7B**: Quantitative Systems Pharmacology
 | **T8A**: Targeting Ocular Disorders | **Wednesday 7-9:30 pm - Dinner Short Courses**
S3: Symposium: Tuesday Designing CRISPR-Based Therapies

PLENARY KEYNOTE PROGRAM

**PLENARY KEYNOTE INTRODUCTION:**

**Comprehensive Kinase and Epigenetic Compound Profiling**

*Kelvin Lam, Ph.D., Director, Strategic Partnerships, Reaction Biology Corporation*

Kinase inhibitors can be used as chemical probes to understand signal transduction pathways. Since the majority of kinase probes inhibit multiple kinases, understanding the off-target effects will allow scientists to design better poly-pharmacologic compounds to meet specific therapeutic needs. Profiling a compound against the entire kinase gene family will allow us to understand the compound’s full enzymatic activities. Unexpected activities could lead to different chemical design and possibly novel therapeutic opportunities. Reaction Biology offers large-scale *in vitro* kinase and epigenetic profiling services for (1) compound prioritizing and (2) elucidating novel activities for kinase and epigenetic inhibitors.

**iPS Cell Technology, Gene Editing and Disease Research**

*Rudolf Jaenisch, M.D., Founding Member, Whitehead Institute for Biomedical Research; Professor, Department of Biology, Massachusetts Institute of Technology*

The development of the iPS cell technology has revolutionized our ability to study human diseases in defined *in vitro* cell culture systems. A major problem of using iPS cells for this “disease in the dish” approach is the choice of control cells because the unpredictable variability between different iPS / ES cells to differentiate into a given lineage. Recently developed efficient gene editing methods such as the CRISPR/Cas system allow the creation of genetically defined models of monogenic as well as polygenic human disorders.

**The Evolutionary Dynamics and Treatment of Cancer**

*Martin Nowak, Ph.D., M.Sc., Professor, Biology and Mathematics and Director, Program for Evolutionary Dynamics, Harvard University*

Cancer is an evolutionary process. Cancer initiation and progression are caused by somatic mutation and selection of dividing cells. The mathematical theory of evolution can therefore provide quantitative insights into human cancer.

Cambridge Healthtech Institute will host its **13th Annual Discovery on Target** event showcasing current and emerging “hot” targets for the pharmaceutical industry September 21-24, 2015 in Boston, MA. Spanning five days, the event attracts 1,000+ attendees (from 21 countries), composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations. In 2015 the event is comprised of 15 conference tracks, 3 Symposia, 15 short courses, 35+ interactive breakout discussion groups, an exhibit hall of 65 companies, and dedicated poster viewing and networking sessions. The **13th Annual Discovery on Target** event assembles an impressive group of 200+ distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees.

**Maximize your experience on-site at Discovery on Target 2015!**
The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people you want to meet. This online system was designed with your privacy in mind and is available only to registered session attendees of this event. Registered conference attendees will receive more information on accessing the Intro-Net in the weeks leading up to the event.

**PREMIER SPONSORS**

**CORPORATE SPONSORS**

![CELLECTA](https://example.com/CELLECTA.png)

![domainex](https://example.com/domainex.png)

![MOLECULAR SENSING](https://example.com/MOLECULARSENSING.png)

![SIGMA-ALDRICH](https://example.com/SIGMAALDRICH.png)

![ROSADevelopment Advisors](https://example.com/ROSADevelopmentAdvisors.png)

![Sigma-Aldrich](https://example.com/SigmaAldrich.png)

![CharlesRiver](https://example.com/CharlesRiver.png)

![AXIOMX](https://example.com/AXIOMX.png)

![CALIXAR](https://example.com/CALIXAR.png)

![EUROFINS](https://example.com/EUROFINS.png)

![GE Healthcare](https://example.com/GEHealthcare.png)

![INTEGRA](https://example.com/INTEGRA.png)

![INTROGENE](https://example.com/INTROGENE.png)

![PERSOMICS](https://example.com/PERSOMICS.png)

![REACTIBIOLOGYCORP](https://example.com/REACTIBIOLOGYCORP.png)

![SandozPharmaDiscoveryServices](https://example.com/SandozPharmaDiscoveryServices.png)